Novavax, Inc.
NVAXHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeNovavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and. The $1.69B market capitalization puts NVAX squarely in small-cap range for its industry. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Market Cap
$1.69B
Beta
2.45
P/E (TTM)
—
P/E (Fwd)
-16.65
EPS (TTM)
$-1.53
EPS (Fwd)
$-0.61
ROE
—
ROA
-6.5%
Cash
$719.3M
Total Debt
$297.3M
Free CF
$153.4M
52W Change
28.4%
Annual Financials
Cash vs Debt
Where NVAX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NVAX finished 15.57% above its 150-day moving average ($8.93) and 21.13% above its 200-day moving average ($8.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NVAX overbought or oversold?
At the September 3, 2026 close, NVAX's RSI(14) was 75.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $719.3M in cash comfortably exceeding the $297.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $153.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Revenue has been uneven over recent years, ranging from $1.60B to $1.12B.
With a beta above 1.5, NVAX tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Novavax, Inc. and its sector.